Holen Sie sich die Stockscreener-App
28.59
0.07%
0.02
Handel nachbörslich:
28.59
Schlusskurs vom Vortag:
$28.57
Offen:
$28.62
24-Stunden-Volumen:
236.62K
Relative Volume:
0.63
Marktkapitalisierung:
$1.31B
Einnahmen:
$722.68M
Nettoeinkommen (Verlust:
$134.71M
KGV:
10.71
EPS:
2.67
Netto-Cashflow:
$109.94M
1W Leistung:
-0.07%
1M Leistung:
+3.06%
6M Leistung:
+4.50%
1J Leistung:
-11.24%
1-Tages-Spanne:
$28.48
$29.09
1-Wochen-Bereich:
$28.37
$29.46
52-Wochen-Spanne:
$20.39
$32.69
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
28.59 | 1.31B | 722.68M | 134.71M | 109.94M | 2.67 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Market Review: Can Amphastar Pharmaceuticals Inc maintain its current growth rateJuly 2025 Intraday Action & Community Shared Stock Ideas - baoquankhu1.vn
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by New York State Common Retirement Fund - MarketBeat
Market Catalysts: Can Amphastar Pharmaceuticals Inc maintain its current growth rateMarket Growth Summary & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) A Risky Investment? - 富途牛牛
Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline? - Sahm
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Cross Above 50-Day Moving AverageHere's Why - MarketBeat
Is Amphastar Pharmaceuticals Inc. a top pick in the sectorQuarterly Portfolio Report & Safe Capital Investment Plans - mfd.ru
Whale Trades: Is Amphastar Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
SummerHaven Investment Management LLC Takes $1.02 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Unveiling a Potential 18.69% Upside for Investors - DirectorsTalk Interviews
Can Amphastar Pharmaceuticals Inc. maintain its current growth rateJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - mfd.ru
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How Amphastar Pharmaceuticals Inc. (AMPH) Affects Rotational Strategy Timing - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 21% Potential Upside for Investors - DirectorsTalk Interviews
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? - sharewise.com
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving - Finviz
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin - Yahoo Finance
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth - MarketBeat
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead - The Globe and Mail
Aug Opening: Will Amphastar Pharmaceuticals Inc stock recover faster than peers2025 Price Targets & Smart Investment Allocation Tips - Bộ Nội Vụ
Earnings Recap: Will Amphastar Pharmaceuticals Inc stock pay special dividends2025 Big Picture & Capital Protection Trade Alerts - Bộ Nội Vụ
Amphastar licenses synthetic ACTH analog for inflammatory conditions By Investing.com - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook With A 7.39% Upside Potential - DirectorsTalk Interviews
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today - Finviz
Amphastar Licenses ACTH Analog AMP-110 for North America - TipRanks
Amphastar Pharmaceuticals Signs Multiple Material Agreements - TradingView
Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110 - Contract Pharma
Amphastar licenses synthetic ACTH analog for inflammatory conditions - Investing.com
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - ACCESS Newswire
New synthetic hormone treatment targets autoimmune and inflammatory conditions - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Could Be Riskier Than It Looks - 富途牛牛
The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight - Yahoo Finance
(AMPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Amphastar Pharmaceuticals Inc. stock a smart buy before Fed meetingExit Point & Daily Profit Focused Screening - Улправда
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness? - Sahm
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Trimmed by CX Institutional - MarketBeat
Why Amphastar Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - Улправда
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum - Sahm
Will Amphastar Pharmaceuticals Inc. stock benefit from AI adoption2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Amphastar Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Profit Report & High Return Trade Opportunity Guides - ulpravda.ru
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference - ACCESS Newswire
Amphastar Expands BAQSIMI® Distribution in Asia - MSN
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring an 18.69% Upside Potential - DirectorsTalk Interviews
Value Recap: Is Amphastar Pharmaceuticals Inc stock trading near support levels2025 Technical Patterns & Weekly Breakout Watchlists - moha.gov.vn
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc. - MarketBeat
What analysts say about Amphastar Pharmaceuticals Inc stockTake Profit Strategies & Outstanding Investment Portfolio - earlytimes.in
Amphastar Director Sells 16,679 Shares for $441,800 - AOL.com
Amphastar Pharmaceuticals Inc Stock Analysis and ForecastVolatility Index Analysis & Swing Trade Smarter With Data Insights - earlytimes.in
Will Amphastar Pharmaceuticals Inc. stock split again soonStock Screening Results & Make Confident Moves With Forecasting Models - bollywoodhelpline.com
Is Amphastar Pharmaceuticals Inc stock affected by interest rate hikesShort Setup & Reliable Intraday Trade Alerts - moha.gov.vn
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):